Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest minimal residual disease Stories

2014-01-09 23:01:40

Blinatumomab, the first BiTE® antibody to be developed for the treatment of cancer, is being investigated by the ECOG-ACRIN Cancer Research Group in its latest trial, E1910. Philadelphia, PA (PRWEB) January 09, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it has activated E1910, a randomized phase III clinical trial comparing overall survival after treatment with blinatumomab in combination with chemotherapy vs. chemotherapy alone in adults aged 35 to...

2013-12-03 12:27:24

Data Validates Survival Benefit of Minimal Residual Disease by clonoSEQ(TM) in Patients with T and B Cell Malignancies SEATTLE, Dec. 3, 2013 /PRNewswire/ -- Adaptive Biotechnologies, the pioneer of Next Generation Sequencing (NGS) of the adaptive immune system, and its collaborators will present data demonstrating how immunosequencing can inform survival in patients with blood cancers at the American Society of Hematology (ASH) meeting from December 7-10, 2013. (Logo:...

2013-11-15 23:03:44

St. Jude Children’s Research Hospital leads study showing that a drug withdrawn from the market in 2010 may enhance the effectiveness of bone marrow transplants for select pediatric leukemia patients Memphis, Tenn. (PRWEB) November 15, 2013 Combining the drug gemtuzumab ozogamicin (GO) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children’s...

2013-10-17 12:30:16

The allowed claims cover compositions and methods that allow for Next Generation Sequencing (NGS) to be applied to cells of the adaptive immune system SEATTLE, Oct. 17, 2013 /PRNewswire/ -- Adaptive Biotechnologies Corporation, a pioneer in the field of genomic immune profiling, announced today that the Company has obtained a Notice of Allowance in U.S. Patent Application Serial No. 12/794,507, titled "Method of Measuring Adaptive Immunity," exclusively licensed by Adaptive...

2013-10-01 13:34:47

Research by Chronix Biomedical and Institute of Veterinary Medicine Gottingen highlights cell-free DNA analysis for cancer minimal residual disease Researchers from the University Göttingen Institute of Veterinary Medicine and Chronix Biomedical have published a new study exploring the genetic hallmarks of canine mammary cancer. Appearing in the peer-reviewed journal PLOS ONE, the paper identifies important similarities and differences between human and canine breast tumors, providing a...

2013-09-25 04:22:15

SAN DIEGO, Sept. 25, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced the issuance of U.S. Patent 8,501,924, "Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof." The patent pertains to nucleic acid sequences encoding NPM mutants and methods of detecting them for diagnosing acute myeloid leukemia (AML) and monitoring residual AML disease. This is the second issued U.S. patent directed to NPM...

2013-09-13 12:26:09

Award is for a multi-center collaboration with MD Anderson, the Fred Hutchinson Cancer Research Center, City of Hope, Duke University, and the University of Colorado SEATTLE, Sept. 13, 2013 /PRNewswire/ -- Adaptive Biotechnologies announced today that it received a $2.53 million Phase II Small Business Innovation Research award from the National Heart, Lung, and Blood Institute, a division of the NIH, to commercialize a test to measure the ability of a cancer patient's adaptive...

2013-07-09 21:24:33

New evidence suggests that using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions and ultimately predict patient outcomes for patients with a particularly aggressive form of acute lymphocytic leukemia (ALL). Study results were published online today in Blood, the Journal of the American Society of Hematology (ASH). Approximately 25 to 30 percent of all adults with ALL, the second most common...

2013-07-09 12:27:34

WASHINGTON, July 9, 2013 /PRNewswire-USNewswire/ -- New evidence suggests that using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions and ultimately predict patient outcomes for patients with a particularly aggressive form of acute lymphocytic leukemia (ALL). Study results were published online today in Blood, the Journal of the American Society of Hematology (ASH). Approximately 25...

2013-06-27 12:27:52

SEATTLE, June 27, 2013 /PRNewswire/ -- Adaptive Biotechnologies announced today that it has signed an agreement with Biogen Idec for the study of the immune repertoire and the search for immunological biomarkers in difficult to treat autoimmune diseases. (Logo: http://photos.prnewswire.com/prnh/20120103/SF28632LOGO) Under the collaboration, Adaptive's proprietary immune profiling assay, immunoSEQ, will be used to characterize the immune repertoire of patient samples with...